Abstract Oxipurinol (4, 6-dihydroxypyrazolo (3, 4-d) pyrimidine; alloxanthine) is the chief
metabolite of allopurinol in vivo. Like allopurinol, although to a lesser degree, oxipurinol …

Allopurinol is the most commonly used urate lowering therapy in the management of gout.
Despite the fact that it has been available for over 40 years there is ongoing debate about …

In 2003, the uricosuric drug benzbromarone was withdrawn from the market. The first
alternative drug of choice was the xanthine oxidase inhibitor allopurinol. The purpose was to …

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Guidelines recommend that the
therapeutic goal of urate‐lowering therapy (ULT) is to achieve a urate concentration of≤ 6 …

Allopurinol is the mainstay of urate‐lowering therapy for patients with gout and impaired
renal function. Although rare, a life‐threatening hypersensitivity syndrome may occur with …

What is known and objective There are no clinical reports that have compared topiroxostat, a
selective xanthine oxidase inhibitor, with allopurinol in serum urate‐lowering efficacy. The …

OBJECTIVE: Published guidelines state that allopurinol doses should be adjusted according
to creatinine clearance. We investigated whether such dosing provides adequate control of …

Objectives Allopurinol is the most widely prescribed serum uric acid-lowering therapy (ULT)
in gout. To achieve serum uric acid (sUA) concentrations associated with clinical benefit …

Allopurinol is the most widely used urate-lowering drug (ULD). Together with efficacy and
cost, safety is an aspect that helps taking clinical decisions. This systematic review analyzes …

Objective: To review the evidence surrounding the use of allopurinol in chronic kidney
disease (CKD) and discuss safety and efficacy considerations of such use. Data Sources: A …